The CHMP, upon review of the safety of Hexavac, acknowledged the finding of a statistical signal of an excess occurrence of SUD after Hexavac booster vaccination in the 2nd year of life, but also the inability to identify a biological mechanism in spite of meticulous expert considerations, and the initiation of epidemiological studies.